Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KS6F
|
|||
| Former ID |
DNCL002664
|
|||
| Drug Name |
IRX-2
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | ||
| Squamous cell carcinoma [ICD-11: 2B60-2D01] | Phase 2 | [2] | ||
| Breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [3] | ||
| leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Investigative | [4] | ||
| Company |
IRX Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytokine receptor unspecific (CRF) | Target Info | Modulator | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
| REF 5 | Clinical pipeline report, company report or official report of IRX Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.